FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/07/090763 [Registered on: 11/07/2025] Trial Registered Prospectively
Last Modified On: 09/07/2025
Post Graduate Thesis  Yes 
Type of Trial  Observational 
Type of Study   Cross Sectional Study 
Study Design  Other 
Public Title of Study   Usefulness of AFP, PIVKA - II and ASAP score in diagnosis of Hepatocellular Carcinoma and their correlation with disease severity. 
Scientific Title of Study   Diagnostic Utility of AFP, PIVKA-II, and ASAP Score in Hepatocellular Carcinoma (HCC): Correlation with Histopathological and Radiological Tumor Grading  
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Ravi Singhal 
Designation  DNB resident 
Affiliation  Medanta Medicity Gurugram 
Address  Department of Biochemistry, Medanta-The Medicity, CH Baktawar Singh Rd, Medicity, Islampur Colony, Sector 38, Gurugram

Gurgaon
HARYANA
122001
India 
Phone  8076157043  
Fax    
Email  ravisinghal@hotmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Anuj Parkash 
Designation  Associate Director and Head of Department - Biochemistry 
Affiliation  Medanta Medicity Gurugram 
Address  Medanta- The Medicity, CH Baktawar Singh Rd, Medicity, Islampur Colony, Sector 38, Gurugram

Gurgaon
HARYANA
122001
India 
Phone  9643001625  
Fax    
Email  anuj.parkash@medanta.org  
 
Details of Contact Person
Public Query
 
Name  Dr Ravi Singhal 
Designation  DNB resident 
Affiliation  Medanta Medicity Gurugram 
Address  Medanta- The Medicity, CH Baktawar Singh Rd, Medicity, Islampur Colony, Sector 38, Gurugram

Gurgaon
HARYANA
122001
India 
Phone  8076157043  
Fax    
Email  ravisinghal@hotmail.com  
 
Source of Monetary or Material Support  
NIL 
 
Primary Sponsor  
Name  Medanta Medicity Gurugram 
Address  Medanta- The Medicity, CH Baktawar Singh Rd, Medicity, Islampur Colony, Sector 38, Gurugram, Haryana 122001 
Type of Sponsor  Private hospital/clinic 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Ravi Singhal  Medanta Medicity Gurgaon  Medanta- The Medicity, CH Baktawar Singh Rd, Medicity, Islampur Colony, Sector 38, Gurugram, Haryana 122001
Gurgaon
HARYANA 
8076157043

ravisinghal@hotmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Medanta Institutional Ethics Committee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: C220||Liver cell carcinoma,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Nil  Nil 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  90.00 Year(s)
Gender  Both 
Details  Adults more than 18 years

Patients with newly diagnosed radiologically or histologically confirmed HCC.

Patients in which histopathological tumor grading has been done as per the WHO Grading system for Hepatocellular Carcinoma, radiological grading done as per on Li-RADS and severity (tumor staging/extent of disease) determined as per Barcelona Clinic Liver Cancer (BCLC) Staging.
 
 
ExclusionCriteria 
Details   
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
-Primary Objective – To determine the Diagnostic value of AFP, PIVKA – II, and combined ASAP score in diagnosis of Hepatocellular Carcinoma.



 
At end of the study, 12 months.


 
 
Secondary Outcome  
Outcome  TimePoints 
-Secondary Objective – Correlation of AFP levels, PIVKA-II levels, & combined ASAP score to histopathological, radiological, & clinical tumor grading.  At end of study 12 months. 
 
Target Sample Size   Total Sample Size="90"
Sample Size from India="90" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   21/07/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and a leading cause of cancer-related deaths worldwide. Its incidence is steadily increasing due to the global rise in chronic liver diseases such as hepatitis B and C, alcoholic liver disease, and metabolic dysfunction – associated steatotic liver disease (MASLD). Early detection remains critical, as 30–40% of patients present at advanced stages with limited treatment options and a 5-year survival rate below 20%.

 Serum alpha-fetoprotein (AFP), a glycoprotein elevated in 60–70% of HCC cases, has traditionally been used for screening but suffers from poor sensitivity (18–60%) and specificity (85–90%), particularly in early-stage tumours. For instance, AFP fails to detect 80% of HCC nodules <3 cm, and its levels can rise non-specifically during hepatic inflammation or regeneration. 

 In recent years, des-gamma-carboxy prothrombin, also known as PIVKA-II (Protein Induced by Vitamin K Antagonist-II), has emerged as a promising complementary biomarker with better performance in certain clinical settings. Studies have reported 81.55 % sensitivity and 86 % specificity at cutoff values of 43.47 mAU/mL. Unlike AFP, PIVKA-II levels correlate with tumour aggressiveness and vascular invasion, making it valuable for monitoring progression. 

 To enhance diagnostic accuracy, composite scoring systems such as the ASAP score—which integrates Age, Sex, AFP, and PIVKA-II—have been developed and evaluated in various populations. These multiparametric tools may improve early detection and allow risk stratification, but their clinical utility in different ethnic and demographic groups, including the Indian population, remains underexplored.

 Moreover, the correlation between biomarker levels and the histological grade or clinical stage of HCC could provide valuable prognostic insights and support the development of personalized therapeutic strategies .

This study aims to compare the diagnostic efficacy of AFP, PIVKA-II, and the ASAP score in the detection of HCC and to analyse their correlation with tumour grade and severity in a population mix in Tertiary care Hospital, thereby contributing to a more refined and personalized approach to HCC diagnosis.

 
Close